Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines

Research in Veterinary Science

Volumn 96, Issue 3, 2014, Pages 482-486

  Seo, Kyoung won ^a   Coh, Ye rin ^b   Rebhun, Robert B ^c   Ahn, Jin ok ^b   Han, Sei Myung ^b   Lee, Hee woo ^b   Youn, Hwa Young ^b  

^a Chungnam National University   (South Korea)

^b Seoul National University   (South Korea)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antitumor effects; Canine melanoma; Celecoxib; COX 2 inhibitors

Indexed keywords

CASPASE 3; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG MECHANISM; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; MELANOMA CELL LINE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DOG DISEASES; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; MELANOMA; METABOLISM; MOUTH NEOPLASMS; PHYSIOLOGY; TUMOR CELL LINE; VETERINARY; WESTERN BLOTTING;

CANIS FAMILIARIS;

ANIMALS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOG DISEASES; DOGS; FLOW CYTOMETRY; MELANOMA; MOUTH NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84899949575     PISSN: 00345288     EISSN: 15322661     Source Type: Journal    
DOI: 10.1016/j.rvsc.2014.03.003     Document Type: Article

References (31)

1. Basu G.D., Pathangey L.B., Tinder T.L., Gendler S.J., Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Research 2005, 7:R422-R435.
2. Bocca C., Bozzo F., Bassignana A., Miglietta A. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Molecular and Cellular Biochemistry 2011, 350:59-70.
3. Bundscherer A., Hafner C., Maisch T., Becker B., Landthaler M., Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncology Reports 2008, 19:547-553.
4. Dhawan D., Craig B.A., Cheng L., Snyder P.W., Mohammed S.I., Stewart J.C., et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Molecular Cancer Therapeutics 2010, 9:1371-1377.
5. El-Rayes B.F., Ali S., Sarkar F.H., Philip P.A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Molecular Cancer Therapeutics 2004, 3:1421-1426.
6. Gogas H., Polyzos A., Stavrinidis I., Frangia K., Tsoutsos D., Panagiotou P., et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Annals of Oncology 2006, 17:1835-1841.
7. Goldschmidt M.H. Benign and malignant melanocytic neoplasms of domestic animals. The American Journal of Dermatopathology 1985, 7(Suppl.):203-212.
8. Gupta S., Adhami V.M., Subbarayan M., MacLennan G.T., Lewin J.S., Hafeli U.O., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Research 2004, 64:3334-3343.
9. Herschman H.R. Prostaglandin synthase 2. Biochimica et Biophysica Acta 1996, 1299:125-140.
10. Inoue K., Ohashi E., Kadosawa T., Hong S.H., Matsunaga S., Mochizuki M., et al. Establishment and characterization of four canine melanoma cell lines. The Journal of Veterinary Medical Science 2004, 66:1437-1440.
11. Kim Y.Y., Lee E.J., Kim Y.K., Kim S.M., Park J.Y., Myoung H., et al. Anti-cancer effects of celecoxib in head and neck carcinoma. Molecules and Cells 2010, 29:185-194.
12. Kuzbicki L., Sarnecka A., Chwirot B.W. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Research 2006, 16:29-36.
13. Lanza-Jacoby S., Dicker A.P., Miller S., Rosato F.E., Flynn J.T., Lavorgna S.N., et al. Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Molecular Cancer Therapeutics 2004, 3:417-424.
14. Lei Z., Tan I.B., Das K., Deng N., Zouridis H., Pattison S., et al. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. Gastroenterology 2013, 145:554-565.
15. Li M., Wu X., Xu X.C. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. International Journal of Cancer. Journal International du Cancer 2001, 93:218-223.
16. Liu H., Huang P., Xu X., Liu J., Guo C. Anticancer effect of celecoxib via COX-2 dependent and independent mechanisms in human gastric cancers cells. Digestive Diseases and Sciences 2009, 54:1418-1424.
17. Lotan R. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Research 1979, 39:1014-1019.
18. Maier T.J., Schilling K., Schmidt R., Geisslinger G., Grösch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochemical Pharmacology 2004, 67:1469-1478.
19. Mohammed S.I., Coffman K., Glickman N.W., Hayek M.G., Waters D.J., Schlittler D., et al. Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2001, 64:1-4.
20. Mohammed S.I., Coffman K., Glickman N.W., Hayek M.G., Waters D.J., Schlittler D., et al. Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2001, 64:1-4.
21. Narayanan B.A., Condon M.S., Bosland M.C., Narayanan N.K., Reddy B.S. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clinical Cancer Research 2003, 9:3503-3513.
22. North G.L. Celecoxib as adjunctive therapy for treatment of colorectal cancer. The Annals of Pharmacotherapy 2001, 35:1638-1643.
23. Ogilvie G.K., Moore A.S. Managing the Canine Cancer Patient 2006, Veterinary Learning System, Pennsylvania, PA, USA.
24. Patel M.I. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical Cancer Research 2005, 11:1999-2007.
25. Pires I., Garcia A., Prada J., Queiroga F.L. COX-1 and COX-2 expression in canine cutaneous, oral and ocular melanocytic tumours. Journal of Comparative Pathology 2010, 143:142-149.
26. Pyrko P., Kardosh A., Liu Y.T., Soriano N., Xiong W., Chow R.H., et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics 2007, 6:1262-1275.
27. Rigel D.S., Carucci J.A. Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA: A Cancer Journal for Clinicians 2000, 50:215-236. quiz 237-240.
28. Tegeder I., Niederberger E., Israr E., Guhring H., Brune K., Euchenhofer C., et al. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. The FASEB Journal 2001, 15:2-4.
29. Wang Z.L., Fan Z.Q., Jiang H.D., Qu J.M. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling. Carcinogenesis 2012, 34:638-646.
30. Withrow S., Vail D.M., Page R.L. Withrow and MacEwen's Small Animal Clinical Oncology 2012, Elsevier Health Sciences, St. Louis, MO, USA.
31. Wu G.S., Zou S.Q., Liu Z.R., Tang Z.H., Wang J.H. Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World Journal of Gastroenterology 2003, 9:1302-1306.